A method for systematically ranking therapeutic drug candidates using multiple uncertain screening criteria.

ABSTRACT: Multiple different screening tests for candidate leads in drug development may often yield conflicting or ambiguous results, sometimes making the selection of leads a nontrivial maximum-likelihood ranking problem. Here, we employ methods from the field of multiple criteria decision making (MCDM) to the problem of screening candidate antibody therapeutics. We employ the SMAA-TOPSIS method to rank a large cohort of antibodies using up to eight weighted screening criteria, in order to find lead candidate therapeutics for Alzheimer's disease, and determine their robustness to both uncertainty in screening measurements, as well as uncertainty in the user-defined weights of importance attributed to each screening criterion. To choose lead candidates and measure the confidence in their ranking, w

SUBMITTER: Peng X 

PROVIDER: S-EPMC8189013 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature